FIG. 3.

Combination oncolytic virotherapy and adoptive T-cell therapy for metastatic disease. Naïve OT-I T cells (1 × 10⁶) were adoptively transferred into C57BL/6 mice bearing two B16ova tumors that had been established on both flanks 7 days previously (eight mice/group). On the same day, tumors on the right flank were injected intratumorally with 5 × 10⁸ PFU of HI virus, VSV-GFP, or VSV-ova every other day for six injections. (A) Survival (tumor less than 1.0 cm in any diameter) or (B–E) growth of individual tumors is shown.